Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

NCT05819138 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: Semaglutide Pen Injector
DRUG: Placebo

Sponsor

University of Colorado, Denver

Collaborators

[object Object]